Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PRME files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPrime Medicine appoints Svetlana Makhni as CFO with $495K salary and 800K stock options
Filed April 16, 2026 · Period ending April 7, 2026 · ~1 min read
Key Changes
-
high
Svetlana Makhni appointed CFO effective April 16, 2026, bringing 20+ years biotech finance experience including recent CFO role at Marengo Therapeutics. CEO Allan Reine steps down as principal financial officer but continues as CEO.
Item 5.02 verify on EDGAR → -
high
Board granted Makhni stock options for 800,000 shares (4-year vest: 25% at year one, monthly thereafter) plus 100,000 performance-based options. Exercise price set at grant date closing price on Nasdaq.
Item 5.02 verify on EDGAR → -
medium
Compensation package includes $495,000 base salary, $40,000 sign-on bonus, and 40% target annual bonus (approximately $198,000). Total first-year cash compensation around $733,000.
Item 5.02 verify on EDGAR → -
medium
Severance terms provide 9 months salary plus 0.75x target bonus if terminated without cause. Change-of-control termination triggers 12 months salary, 1.0x bonus, and full equity acceleration.
Item 5.02 verify on EDGAR →
Summary
Prime Medicine has formalized its executive structure by appointing Svetlana Makhni as Chief Financial Officer, ending CEO Allan Reine's dual role as principal financial officer. Makhni brings substantial biotech finance credentials from her recent CFO position at Marengo Therapeutics and two decades of industry experience.
The appointment signals the company's maturation from startup-style leadership to a more traditional corporate structure with dedicated financial leadership. The compensation package is competitive for a biotech CFO at a company of Prime's stage, with the 800,000-share option grant representing meaningful potential dilution that shareholders should monitor.
At current trading levels, this equity could represent significant value if the company's gene editing platform advances successfully. The performance-based 100,000 additional options suggest the Board has tied part of her compensation to specific milestones. Investors should watch for Makhni's first earnings call and any updates to financial guidance or capital allocation strategy. Her background in investment banking may signal preparation for future financing activities or strategic transactions. The transition from CEO-led finances to dedicated CFO oversight typically improves financial controls and investor communication quality.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 7, 2026, the Board of Directors (the “Board”) of Prime Medicine, Inc. (the “Company”) appointed Svetlana Makhni as the Chief Financial Officer and the principal financial officer of the Company effective as of April 16, 2026.
Prime Medicine appointed Svetlana Makhni as Chief Financial Officer and principal financial officer effective April 16, 2026. Ms. Makhni brings over 20 years of experience in biotechnology CFO roles and investment banking, most recently serving as CFO of Marengo Therapeutics from June 2022 to April 2026.
Added in current filing · verify on EDGAR →
Effective as of April 16, 2026, Allan Reine, M.D. will step down from the role of principal financial officer for purposes of Section 16 of the Exchange Act, as amended, and will continue in his role of Chief Executive Officer and principal executive officer of the Company.
CEO Allan Reine is stepping down from the principal financial officer role effective April 16, 2026, but will continue as CEO and principal executive officer. This represents a transition from the CEO holding dual roles to a dedicated CFO structure.
Event · Item 9.01 — Financial Statements and Exhibits
Prime Medicine filed an employment agreement for Svetlana Makhni effective April 16, 2026.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Employment Agreement, effective as of April 16, 2026, by and between Prime Medicine, Inc. and Svetlana Makhni
Prime Medicine entered into an employment agreement with Svetlana Makhni effective April 16, 2026. The 8-K does not disclose the role, compensation, or other material terms of the agreement.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify